Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Source:

Nursing2015

December 2012, Volume 42 Number 12 , p 8 - 9

Authors

Abstract

The FDA recently approved adalimumab (Humira) for treatment of moderate-to-severe ulcerative colitis in adults when treatment with other immunosuppressants has failed. Adalimumab had been approved previously to treat various other disorders, including rheumatoid arthritis, plaque psoriasis, and Crohn disease. Classified as a tumor necrosis factor blocker, adalimumab blocks the proteins that help spark abnormal inflammatory and immune responses.Adalimumab should be continued only in patients with evidence of clinical remission by the eighth week of therapy. The most common adverse reactions include infections, such as upper respiratory tract infections and sinusitis, injection site reactions, headache, and rash. Adalimumab carries a boxed warning because of the risk of serious infection and malignancy.Source: FDA approves Humira to treat ulcerative colitis. FDA news release. 2012; September 28.After myocardial infarction (MI), beta-blockers are a standard treatment. But do they benefit patients with no recent history of MI? To find out, researchers examined the use of beta-blockers in three groups: stable patients with a remote history of MI, patients with coronary artery disease (CAD) but no history of MI, and patients with only risk factors for CAD. The observational study included 44,708 patients with a follow-up (median) of 44 months. The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke.Event outcomes weren't significantly different in patients taking beta-blockers compared with those not taking beta-blockers. However, risk of the primary outcome was higher for patients taking beta-blockers in the group of patients with CAD risk factors only.Researchers concluded that the use of beta-blockers wasn't associated with a lower risk of composite cardiovascular events in any of the three study groups.Source: Bangalore S, Steg G, Deedwania P, et al. [beta]-blocker use and clinical outcomes in stable outpatients with and without coronary

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: